Loriot Y - Search Results

1

Tumor growth rate provides useful information to evaluate sorafenib and everolimus treatment in metastatic renal cell carcinoma patients: an integrated analysis of the TARGET and RECORD phase 3 trial data.

Ferté C, Koscielny S, Albiges L, Rocher L, Soria JC, Iacovelli R, Loriot Y, Fizazi K, Escudier B. Ferté C, et al. Among authors: loriot y. Eur Urol. 2014 Apr;65(4):713-20. doi: 10.1016/j.eururo.2013.08.010. Epub 2013 Aug 15. Eur Urol. 2014. PMID: 23993162 Clinical Trial.

2

[Management of localized germ-cell tumours of the testis].

Loriot Y, Fizazi K. Loriot Y, et al. Rev Prat. 2007 Feb 28;57(4):379-84. Rev Prat. 2007. PMID: 17455739 Review. French.

3

[Management of clinical stage I testicular germ cell tumours].

Loriot Y, Fizazi K. Loriot Y, et al. Bull Cancer. 2007 May;94(5):439-48. Bull Cancer. 2007. PMID: 17535781 Review. French.

4

Drug insight: gastrointestinal and hepatic adverse effects of molecular-targeted agents in cancer therapy.

Loriot Y, Perlemuter G, Malka D, Penault-Llorca F, Boige V, Deutsch E, Massard C, Armand JP, Soria JC. Loriot Y, et al. Nat Clin Pract Oncol. 2008 May;5(5):268-78. doi: 10.1038/ncponc1087. Epub 2008 Mar 18. Nat Clin Pract Oncol. 2008. PMID: 18349858 Review.

5

MVP and vinorelbine for malignant pleural mesothelioma.

Mordant P, Loriot Y, Soria JC, Deutsch E. Mordant P, et al. Among authors: loriot y. Lancet. 2008 Aug 23;372(9639):629; author reply 629-30. doi: 10.1016/S0140-6736(08)61273-8. Lancet. 2008. PMID: 18722865 No abstract available.

6

Combining carboplatin and etoposide in docetaxel-pretreated patients with castration-resistant prostate cancer: a prospective study evaluating also neuroendocrine features.

Loriot Y, Massard C, Gross-Goupil M, Di Palma M, Escudier B, Bossi A, Fizazi K. Loriot Y, et al. Ann Oncol. 2009 Apr;20(4):703-8. doi: 10.1093/annonc/mdn694. Epub 2009 Jan 29. Ann Oncol. 2009. PMID: 19179557 Free article.

7

Wound healing delay after central venous access following DCF/VEGF-trap therapy.

Ferté C, Massard C, Moldovan C, Desruennes E, Loriot Y, Soria JC. Ferté C, et al. Among authors: loriot y. Invest New Drugs. 2009 Dec;27(6):583-5. doi: 10.1007/s10637-009-9227-7. Epub 2009 Feb 17. Invest New Drugs. 2009. PMID: 19221694

8

Phase II trial of consolidation docetaxel and samarium-153 in patients with bone metastases from castration-resistant prostate cancer.

Fizazi K, Beuzeboc P, Lumbroso J, Haddad V, Massard C, Gross-Goupil M, Di Palma M, Escudier B, Theodore C, Loriot Y, Tournay E, Bouzy J, Laplanche A. Fizazi K, et al. Among authors: loriot y. J Clin Oncol. 2009 May 20;27(15):2429-35. doi: 10.1200/JCO.2008.18.9811. Epub 2009 Apr 13. J Clin Oncol. 2009. PMID: 19364971 Clinical Trial.

9

Diethylstilbestrol (DES) retains activity and is a reasonable option in patients previously treated with docetaxel for castration-resistant prostate cancer.

Serrate C, Loriot Y, De La Motte Rouge T, Gross-Goupil M, Massard C, Escudier B, Bossi A, Fizazi K. Serrate C, et al. Among authors: loriot y. Ann Oncol. 2009 May;20(5):965. doi: 10.1093/annonc/mdp112. Ann Oncol. 2009. PMID: 19403938 Free article. No abstract available.

10

Reversible cardiogenic shock following 5-fluorouracil infusion.

Ferté C, Gomez Roca C, Loriot Y, Bahleda R, Moldovan C, Cohen A, Izzedine H, Soria JC, Ederhy S. Ferté C, et al. Among authors: loriot y. Invest New Drugs. 2010 Aug;28(4):531-3. doi: 10.1007/s10637-009-9271-3. Epub 2009 Jun 5. Invest New Drugs. 2010. PMID: 19499187

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

307 results

Search Page

Filters